Fetal hypoplastic left heart syndrome and maternal liver transplantation for Wilson’s disease: a case report
- 946 Downloads
Liver transplantation currently represents the only curative treatment for Wilson’s disease. A lifelong immunosuppressive therapy is mandatory. In spite of increased maternal and fetal risks, pregnancies after liver transplantation have been reported with favorable perinatal outcomes. Hypoplastic left heart syndrome is a spectrum of congenital heart defects that results in the inability to support the systemic circulation. Although its etiology remains elusive, the prognosis of this previously fatal condition has dramatically improved over the last 2 decades mainly due to advances in prenatal diagnosis, surgical technique and perioperative care.
We present a case of a Caucasian 26-year-old woman, gravida 2, para 1 at 36+0 weeks of gestation who had received a liver transplantation due to Wilson’s disease and subsequently delivered a child with hypoplastic left heart syndrome.
This coincidence of medical conditions has not been described in the literature so far and its implications for mother and child as well as the pathophysiological mechanisms are discussed on the basis of a literature review.
KeywordsHypoplastic left heart syndrome Immunosuppression Liver transplantation Malformation Teratogenicity Wilson’s disease
Hypoplastic left heart syndrome.
Several acquired, inherited or autoimmune hepatic disorders can necessitate liver transplantation. Wilson’s disease is a rare autosomal recessive disorder of copper metabolism that can lead to hepatic failure and neurological degeneration. The underlying mechanism is a mutation of the copper-transporting adenosine triphosphatase gene (ATP7B) located on the long arm of chromosome 13. The worldwide prevalence is 1 in 30,000. Clinical manifestation due to copper accumulation is highly variable, ranging from mild hepatitis to acute liver failure and cirrhosis. Liver transplantation with lifelong immunosuppressive therapy represents the only curative treatment .
Hypoplastic left heart syndrome (HLHS) is a congenital heart defect characterized by variable hypoplasia of the left ventricle, stenosis or atresia of mitral and/or aortic valves and aortic arch hypoplasia, resulting in the inability of the left side of the heart to support the systemic circulation. This cardiac malformation occurs in about 0.02% of all live births. The etiology of HLHS is not yet fully understood but a multifactorial pathogenesis can be assumed. Risk factors might include familial, infectious, maternal and gestational conditions. A genetic influence seems probable although no specific gene has been identified so far. Whether maternal immunosuppression during pregnancy can cause HLHS is unknown [2, 3].
The first pregnancy in a liver transplant recipient was reported by Walcott et al. in 1978 . Since then, hundreds of pregnancies after orthotopic liver transplantation have been reported with favorable perinatal outcomes. We present a case of HLHS after maternal liver transplantation in adolescence due to Wilson’s disease and discuss the potential chain of cause and effect.
A Caucasian 26-year-old woman, gravida 2, para 1 at 36+0 weeks of gestation was admitted to our hospital with fetal HLHS and contractions, not affecting her cervix. She had received a liver transplant at 16 years of age because of acute liver failure due to Wilson’s disease. Her immunosuppression was maintained with tacrolimus. Her first pregnancy at the age of 21 years had been uneventful.
Primary re-cesarean section was performed at 37+0 weeks of gestational age. A male neonate weighing 3380 g was delivered, his APGAR scores (the criteria are appearance, pulse, grimace, activity and respiration) were 8, 9 and 10, pH was 7.24 and base excess −2.8.
After delivery the mother was in perfect health, no rejection episode was observed and discharge was possible after 5 days. Immunosuppressive therapy was continued postnatally with tacrolimus adapted to serum blood levels.
We describe a case of HLHS after maternal liver transplantation due to Wilson’s disease. The most important risks for the fetus in mothers with a liver transplant are preterm delivery (31%) and low birth weight (23%). Attributed maternal risks are pregnancy-induced hypertension, preeclampsia and infection during pregnancy .
In patients who have had liver transplantation no significantly higher incidence of malformation patterns has been shown . Abortions occur more often in transplant recipients whose underlying disease was autoimmune cirrhosis than in recipients with inherited disorders such as Wilson’s disease . Wilson’s disease has not been associated with an increased risk for other genetic disorders.
Dei Malatesta et al. found that higher rates of both abortions (19%) and pregnancy complications in a transplantation collective were inversely related to the time interval between transplantation and conception . While the timing of pregnancy is controversially discussed, current recommendations are to wait for at least 1 year after liver transplantation . Despite the fact that the incidence of malformations is not higher in newborns after maternal liver transplantation compared to the general population, malformation patterns including severe heart defects could potentially account for the higher abortion rates .
The etiology of HLHS remains unknown but may include chromosomal, genetic, infectious, immunosuppressive, teratogenic conditions and other factors .
Although a genetic involvement is strongly suspected, no single gene has been identified to cause HLHS. Chromosomal anomalies occur in up to 5 to 12% of children with HLHS and an association with Turner’s syndrome as well as trisomy 18 and 13 has been described. The genetic alteration most commonly associated with HLHS is the terminal 11q deletion (Jacobsen’s syndrome) in which the incidence of HLHS is 10% . The recurrence risk of HLHS is estimated to be 2 to 4% when a previous newborn was affected [8, 9]. ATP7B is the gene product of the Wilson’s disease gene and is located on chromosome 13. More than 300 different mutations have been identified to date . In Europe the most common mutation is the point mutation H1069Q in exon 14, which underlies 30 to 60% of all mutations in Caucasians . A direct linkage between this gene defect in the mother and HLHS in the child seems to be not possible.
Immunosuppressants and their side effects in pregnant liver transplant recipients
In the mother
In the fetus
IL-2 synthesis inhibition
Hypertension Gestational diabetes Osteonecrosis Cataracts Striae
Malformation (4%, esp. cleft palate) Low birth weight PROM Adrenal suppression Infection
Inhibition of cytokine production
Hypertension Gestational diabetes Renal dysfunction Uterine dystonia Seizures
Malformation (3–5%; no consistent pattern known) Low birth weight Jaundice Cytopenia Hypoglycemia Intracerebral hemorrhage
Antimetabolic: inhibition of the biosynthesis of purine nucleotides
Leukopenia Gastrointestinal side effects
Malformation (7%; esp. aphallia, hypo- or dysplasia of lungs and urinary bladder) IUGR Premature delivery Adrenal hypoplasia Infection
Inhibition of T-lymphocytes activation by inhibition of calcineurin
Hypertension Gestational diabetes Renal dysfunction Neurotoxicity Diarrhea Alopecia Pruritus
Malformation (6%; no consistent pattern known) Transient increase of potassium Impaired renal function
Inhibition of de novo synthesis of purines
Leukopenia Gastrointestinal side effects
Malformation (22%; esp. cleft lip and palate, micrognathia, ear malformations) 1st trimester fetal loss Anemia
Teratogenic agents can cause anatomical defects in the child, for example valproic acid. In terms of immunosuppression due to post-transplant prevention of graft rejection, potential benefits may outweigh these risks (Table 1). A person can also be immunosuppressed for a broad spectrum of other reasons, for example severe combined immunodeficiency or human immunodeficiency virus and rheumatic diseases. So far, no direct association between immunosuppressive treatment after liver transplantation and fetal heart malformation has been established. In particular, there is no evidence of an increased rate of fetal HLHS in immunosuppressed mothers. Although for tacrolimus the malformation rate is estimated to be 6%, several studies and reports confirm the safety of tacrolimus during pregnancy after transplantation [17, 18, 19].
Not a single case of HLHS has been described in connection with immunosuppression until now. We therefore feel that the likelihood of a causal relationship between tacrolimus therapy of the mother during pregnancy and HLHS in the fetus is low, in particular because the mother had delivered a healthy older child and had no history of abortions.
In summary, liver transplantation affects pregnancy and fetal outcome, but an association with severe congenital heart defects or other malformations in newborns has not been established. However, it has to be considered that data may be limited due to underreporting or a small number of cases. The present case of the combination of fetal HLHS and maternal liver transplantation due to Wilson’s disease is probably coincidental, as there is little evidence in the literature for an underlying causal mechanism.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- 7.Armenti VT, Radomski JS, Moritz MJ, Gaughan WJ, Gulati R, McGrory CH: Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl. 2005, 69-83.Google Scholar
- 16.Goldstein LH, Dolinsky G, Greenberg R, Schaefer C, Cohen-Kerem R, Diav-Citrin O, Malm H, Reuvers-Lodewijks ME, van Rost van Tonningen-van Driel MM, Arnon J, Ornoy A, Clementi M, Di Gianantonio E, Koren G, Braunstein R, Berkovitch M:Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol. 2007, 79: 696-701. 10.1002/bdra.20399.CrossRefPubMedGoogle Scholar
- 19.Jain AB, Reyes J, Marcos A, Mazariegos G, Eghtesad B, Fontes PA, Cacciarelli TV, Marsh JW: Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. Transplant. 2003, 76: 827-832. 10.1097/01.TP.0000084823.89528.89.CrossRefGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.